In the last three months, Ginkgo Bioworks' (NYSE: DNA) shares fell by 50%. To the enterprising investor, such a decline by the Boston-based biotech specialist isn't necessarily a sign of disaster, and ...

Cathie Wood-led Ark Invest on Friday snapped up more shares in Ginkgo Bioworks Holdings Inc DNA on the dip. The popular money manager’s investment firm snapped up 1.53 million shares — estimated to be ...

The company's cell engineering platform combines robotics and artificial intelligence (AI) to produce new cell lines for its clients. This is important because many top-selling drugs are manufactured ...

Cathie Wood-led Ark Invest on Wednesday snapped up shares in Ginkgo Bioworks Holdings Inc (NYSE:DNA) on the day the synthetic biology company stock was hit hard by two back-to-back short-seller ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

It has been difficult to be a shareholder of Ginkgo Bioworks (NYSE: DNA) over the past year. The stock has collapsed about 72% from its peak last summer. The company's cell engineering foundry is an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cathie Wood's funds snapped up more than 8 million shares in Ginkgo Bioworks on Wednesday, as the stock plunged as much as 24% in the wake of a report that called it a "Frankenstein mash-up of the ...

On May 9, Ginkgo reported its first-quarter earnings, and, by some measures, it missed the mark. Revenue from its biofoundry segment was $28 million, 18% less than a year prior. While it succeeded in ...